Lotus Pharmaceutical Co., Ltd. Stock Taipei Exchange

Equities

1795

TW0001795003

Pharmaceuticals

End-of-day quote Taipei Exchange 06:00:00 2019-12-12 pm EST 5-day change 1st Jan Change
108 TWD +0.47% Intraday chart for Lotus Pharmaceutical Co., Ltd. -4.42% -.--%
Sales 2024 * 18.82B 578M Sales 2025 * 21.2B 651M Capitalization 82.51B 2.53B
Net income 2024 * 4.84B 149M Net income 2025 * 6.2B 190M EV / Sales 2024 * 4.69 x
Net Debt 2024 * 5.71B 175M Net Debt 2025 * 1.56B 47.99M EV / Sales 2025 * 3.97 x
P/E ratio 2024 *
16.9 x
P/E ratio 2025 *
13.8 x
Employees -
Yield 2024 *
1.71%
Yield 2025 *
2.4%
Free-Float 48.47%
More Fundamentals * Assessed data
Dynamic Chart
Lotus Pharmaceutical Co., Ltd. Announces Change in Representative of the Company's Institutional Director CI
Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Lotus Pharmaceutical Co., Ltd. Announces the Appointment of Valerie Lau as APAC Chief Commercial Officer, Effective February 15, 2024 CI
Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Transcript : Lotus Pharmaceutical Co., Ltd., Q3 2023 Earnings Call, Nov 14, 2023
Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Alvogen Korea Holdings Ltd. announced that it expects to receive KRW 29.51962949 billion in funding from Lotus Pharmaceutical Co., Ltd. CI
Lotus Pharmaceutical Co., Ltd. Announces Director Changes CI
Lotus Pharmaceutical Co., Ltd. and Fuji Pharma Co., Ltd. Joint Product Receives the Approval for Lenalidomide Capsules,2.5 Mg and 5 Mg from the Japan Pmda CI
Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Amarin and Lotus Pharmaceuticals Announce Exclusive Partnership Agreement to Commercialize Vazkepa® (Icosapent Ethyl) in Southeast Asia and South Korea CI
PharmaMar Secures Taiwan Regulatory Approval for Lung Cancer Treatment MT
Lotus Pharmaceutical Co., Ltd. Appoints Susan Liao as Acting Spokesperson CI
Lotus Pharmaceutical Co., Ltd. Announces Appointment of the Remuneration Committee Members CI
Lotus Pharmaceutical Announces Cash Distribution Payable on August 1, 2023 CI
More news

Latest transcript on Lotus Pharmaceutical Co., Ltd.

Managers TitleAgeSince
Chief Executive Officer - 14-09-28
Director of Finance/CFO - 16-10-31
Chief Operating Officer - 22-11-30
Members of the board TitleAgeSince
Director/Board Member 60 14-08-10
Director/Board Member 61 15-04-22
Director/Board Member 57 14-08-10
More insiders
Lotus Pharmaceutical Co Ltd is a Taiwan-based company mainly engaged in the manufacture and sale of generic drugs. The products are mainly solid preparations such as tablets and capsules. The main products include oral anti-cancer drugs, cardiovascular disease drugs, central nervous system drugs, women's health products, osteoporosis drugs and mental disease drugs. The Company is also engaged in the drug research, development and clinical testing business, as well as the product licensing business. The Company mainly distributes products in Taiwan, South Korea, the United States, China mainland, Japan, Europe and Southeast Asia markets.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
312 TWD
Average target price
390.2 TWD
Spread / Average Target
+25.06%
Consensus